SINGAPORE -- German pharmaceutical company BioNTech plans to set up a vaccine manufacturing facility in Singapore as early as 2023 to meet future demand in Southeast Asia, the company announced Monday.
BioNTech will invest "hundreds of millions of U.S. dollars" in the new facility, which it said would produce a range of messenger-RNA vaccines and therapeutics for infectious diseases as well as cancer. Company CEO Ugur Sahin did not specify during a press briefing that the Singapore facility will be used to produce COVID-19 vaccines.
